The US inhalable drug market is the largest market in value, estimated at $ 13.28 billion in 2021, with a 6.1% CAGR between 2023-2030.
The market growth is driven in part by many new investigational therapies in development for rare respiratory diseases, such as PAH (pulmonary arterial hypertension) or IPF (idiopathic pulmonary fibrosis), an increasing incidence of Asthma and COPD as well as a growing elderly population.
Interestingly, dry powder inhalers and aerosol based therapies will remain the dominant device types used for inhalable therapies in the future.
Our inhalation coach application, Kata® is ideally suited to support patients using such devices to inhale their therapies.
Kata® is currently licensed as a Class I medical device in the US and Class IIa device in the EU with CE mark.
Contact:
VisionHealth Inc.
6 Dairy Farm Lane
Wayland, MA 01778
USA
